Top

Journal of Experimental & Clinical Cancer Research

Published in:

01-12-2021 | NSCLC | Research

KLF5-induced BBOX1-AS1 contributes to cell malignant phenotypes in non-small cell lung cancer via sponging miR-27a-5p to up-regulate MELK and activate FAK signaling pathway

Authors: Jiang Shi, Chao Yang, Jinlu An, Dexun Hao, Cong Liu, Jumin Liu, Jing Sun, Junguang Jiang

Published in: Journal of Experimental & Clinical Cancer Research | Issue 1/2021

Abstract

Background

Non-small cell lung cancer (NSCLC) is a major histological subtype of lung cancer with high mortality and morbidity. A substantial amount of evidence demonstrates long non-coding RNAs (lncRNA) as critical regulators in tumorigeneis and malignant progression of human cancers. The oncogenic role of BBOX1 anti-sense RNA 1 (BBOX1-AS1) has been reported in several tumors. As yet, the potential functions and mechanisms of BBOX1-AS1 in NSCLC are obscure.

Methods

The gene and protein expression was detected by qRT-PCR and western blot. Cell function was determined by CCK-8, colony forming, would healing and transwell assays. Bioinformatics tools, ChIP assays, dual luciferase reporters system and RNA pull-down experiments were used to examine the interaction between molecules. Subcutaneous tumor models in nude mice were established to investigate in vivo NSCLC cell behavior.

Results

BBOX1-AS1 was highly expressed in NSCLC tissues and cells. High BBOX1-AS1 expression was associated with worse clinical parameters and poor prognosis. BBOX1-AS1 up-regulation was induced by transcription factor KLF5. BBOX1-AS1 deficiency resulted in an inhibition of cell proliferation, migration, invasion and EMT in vitro. Also, knockdown of BBOX1-AS1 suppressed NSCLC xenograft tumor growth in mice in vivo. Mechanistically, BBOX1-AS1 acted act as a competetive “sponge” of miR-27a-5p to promote maternal embryonic leucine zipper kinase (MELK) expression and activate FAK signaling. miR-27a-5p was confirmed as a tumor suppressor in NSCLC. Moreover, BBOX1-AS1-induced increase of cell proliferation, migration, invasion and EMT was greatly reversed due to the overexpression of miR-27a-5p. In addition, the suppressive effect of NSCLC progression owing to BBOX1-AS1 depletion was abated by the up-regulation of MELK. Consistently, BBOX1-AS1-mediated carcinogenicity was attenuated in NSCLC after treatment with a specific MELK inhibitor OTSSP167.

Conclusions

KLF5-induced BBOX1-AS1 exerts tumor-promotive roles in NSCLC via sponging miR-27a-5p to activate MELK/FAK signaling, providing the possibility of employing BBOX1-AS1 as a therapeutic target for NSCLC patients.

Available only for authorised users

Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–424. https://doi.org/10.3322/caac.21492.CrossRefPubMed

Chen Z, Fillmore CM, Hammerman PS, Kim CF, Wong KK. Non-small-cell lung cancers: a heterogeneous set of diseases. Nat Rev Cancer. 2014;14(8):535–46. https://doi.org/10.1038/nrc3775.CrossRefPubMedPubMedCentral

Herbst RS, Morgensztern D, Boshoff C. The biology and management of non-small cell lung cancer. Nature. 2018;553(7689):446–54. https://doi.org/10.1038/nature25183.CrossRefPubMed

Gridelli C, Rossi A, Carbone DP, Guarize J, Karachaliou N, Mok T, et al. Non-small-cell lung cancer. Nat Rev Dis Primers. 2015;1(1):15009. https://doi.org/10.1038/nrdp.2015.9.CrossRefPubMed

Siegel RL, Miller KD, Jemal A. Cancer statistics, 2018. CA Cancer J Clin. 2018;68(1):7–30. https://doi.org/10.3322/caac.21442.CrossRefPubMed

Hirsch FR, Suda K, Wiens J, Bunn PA Jr. New and emerging targeted treatments in advanced non-small-cell lung cancer. Lancet. 2016;388(10048):1012–24. https://doi.org/10.1016/S0140-6736(16)31473-8.CrossRefPubMed

Doroshow DB, Sanmamed MF, Hastings K, Politi K, Rimm DL, Chen L, et al. Immunotherapy in non-small cell lung Cancer: facts and hopes. Clin Cancer Res. 2019;25(15):4592–602. https://doi.org/10.1158/1078-0432.CCR-18-1538.CrossRefPubMedPubMedCentral

Bhat SA, Ahmad SM, Mumtaz PT, Malik AA, Dar MA, Urwat U, et al. Long non-coding RNAs: mechanism of action and functional utility. Noncoding RNA Res. 2016;1(1):43–50. https://doi.org/10.1016/j.ncrna.2016.11.002.CrossRefPubMedPubMedCentral

Sanchez Calle A, Kawamura Y. Emerging roles of long non-coding RNA in cancer. Cancer Sci. 2018;109(7):2093–100. https://doi.org/10.1111/cas.13642.CrossRefPubMedPubMedCentral

10.

Fang Y, Fullwood MJ. Roles, functions, and mechanisms of long non-coding RNAs in Cancer. Genom Proteomics Bioinform. 2016;14(1):42–54. https://doi.org/10.1016/j.gpb.2015.09.006.CrossRef

11.

Chandra Gupta S, Nandan TY. Potential of long non-coding RNAs in cancer patients: from biomarkers to therapeutic targets. Int J Cancer. 2017;140(9):1955–67. https://doi.org/10.1002/ijc.30546.CrossRefPubMed

12.

Ginn L, Shi L, Montagna M, Garofalo M. LncRNAs in non-small-cell lung Cancer. Noncoding RNA. 2020;6(3):25.PubMedCentral

13.

Ricciuti B, Mencaroni C, Paglialunga L, Paciullo F, Crinò L, Chiari R, et al. Long noncoding RNAs: new insights into non-small cell lung cancer biology, diagnosis and therapy. Med Oncol. 2016;33(2):18. https://doi.org/10.1007/s12032-016-0731-2.CrossRefPubMed

14.

Chen Z, Chen X, Lu B, Gu Y, Chen Q, Lei T, et al. Up-regulated LINC01234 promotes non-small-cell lung cancer cell metastasis by activating VAV3 and repressing BTG2 expression. J Hematol Oncol. 2020;13(1):7. https://doi.org/10.1186/s13045-019-0842-2.CrossRefPubMedPubMedCentral

15.

Hua Q, Mi B, Xu F, Wen J, Zhao L, Liu J, et al. Hypoxia-induced lncRNA-AC020978 promotes proliferation and glycolytic metabolism of non-small cell lung cancer by regulating PKM2/HIF-1α axis. Theranostics. 2020;10(11):4762–78. https://doi.org/10.7150/thno.43839.CrossRefPubMedPubMedCentral

16.

Yang Y, Yu Q, Li B, Guan R, Huang C, Yang X. BBOX1-AS1 accelerates gastric Cancer proliferation by sponging miR-3940-3p to Upregulate BIRC5 expression. Dig Dis Sci. 2021;66(4):1054–62. https://doi.org/10.1007/s10620-020-06308-0.

17.

Xu J, Yang B, Wang L, Zhu Y, Zhu X, Xia Z, et al. LncRNA BBOX1-AS1 upregulates HOXC6 expression through miR-361-3p and HuR to drive cervical cancer progression. Cell Prolif. 2020;53(7):e12823. https://doi.org/10.1111/cpr.12823.CrossRefPubMedPubMedCentral

18.

Yao H, Chen R, Yang Y, Jiang J. LncRNA BBOX1-AS1 aggravates the development of ovarian Cancer by sequestering miR-361-3p to augment PODXL expression. Reprod Sci. 2021;28(3):736–44. https://doi.org/10.1007/s43032-020-00366-5.

19.

Liu J, Zhu J, Xiao Z, Wang X, Luo J. BBOX1-AS1 contributes to colorectal cancer progression by sponging hsa-miR-361-3p and targeting SH2B1. FEBS Open Bio. 2020. https://doi.org/10.1002/2211-5463.12802.

20.

Bartonicek N, Maag JL, Dinger ME. Long noncoding RNAs in cancer: mechanisms of action and technological advancements. Mol Cancer. 2016;15(1):43. https://doi.org/10.1186/s12943-016-0530-6.CrossRefPubMedPubMedCentral

21.

Yoon JH, Abdelmohsen K, Gorospe M. Functional interactions among microRNAs and long noncoding RNAs. Semin Cell Dev Biol. 2014;34(4):9–14. https://doi.org/10.1016/j.semcdb.2014.05.015.CrossRefPubMed

22.

Liu C, Li X, Hao Y, Wang F, Cheng Z, Geng H, et al. STAT1-induced upregulation of lncRNA KTN1-AS1 predicts poor prognosis and facilitates non-small cell lung cancer progression via miR-23b/DEPDC1 axis. Aging (Albany NY). 2020;12(9):8680–701. https://doi.org/10.18632/aging.103191.CrossRef

23.

Li C, Zhao W, Pan X, Li X, Yan F, Liu S, et al. LncRNA KTN1-AS1 promotes the progression of non-small cell lung cancer via sponging of miR-130a-5p and activation of PDPK1. Oncogene. 2020;39(39):6157–71. https://doi.org/10.1038/s41388-020-01427-4.CrossRefPubMed

24.

Rashid F, Shah A, Shan G. Long non-coding RNAs in the cytoplasm. Genom Proteomics Bioinform. 2016;14(2):73–80. https://doi.org/10.1016/j.gpb.2016.03.005.CrossRef

25.

Zang X, Qian C, Ruan Y, Xie J, Luo T, Xu B, et al. Higher maternal embryonic leucine zipper kinase mRNA expression level is a poor prognostic factor in non-small-cell lung carcinoma patients. Biomark Med. 2019;13(16):1349–61. https://doi.org/10.2217/bmm-2019-0052.CrossRefPubMed

26.

Yoon H, Dehart JP, Murphy JM, Lim ST. Understanding the roles of FAK in cancer: inhibitors, genetic models, and new insights. J Histochem Cytochem. 2015;63(2):114–28. https://doi.org/10.1369/0022155414561498.CrossRefPubMed

27.

Tang Q, Li W, Zheng X, Ren L, Liu J, Li S, et al. MELK is an oncogenic kinase essential for metastasis, mitotic progression, and programmed death in lung carcinoma. Signal Transduct Target Ther. 2020;5(1):279. https://doi.org/10.1038/s41392-020-00288-3.CrossRefPubMedPubMedCentral

28.

Arbour KC, Riely GJ. Systemic therapy for locally advanced and metastatic non-small cell lung Cancer: a review. JAMA. 2019;322(8):764–74. https://doi.org/10.1001/jama.2019.11058.CrossRefPubMed

29.

Howlader N, Forjaz G, Mooradian MJ, Meza R, Kong CY, Cronin KA, et al. The effect of advances in lung-Cancer treatment on population mortality. N Engl J Med. 2020;383(7):640–9. https://doi.org/10.1056/NEJMoa1916623.CrossRefPubMedPubMedCentral

30.

Chi Y, Wang D, Wang J, Yu W, Yang J. Long non-coding RNA in the pathogenesis of cancers. Cells. 2019;8(9):1015. https://doi.org/10.3390/cells8091015.CrossRefPubMedCentral

31.

Weidle UH, Birzele F, Kollmorgen G, Rüger R. Long non-coding RNAs and their role in metastasis. Cancer Genomics Proteomics. 2017;14(3):143–60. https://doi.org/10.21873/cgp.20027.CrossRefPubMedPubMedCentral

32.

Yang J, Zhao S. SP1-mediated lncRNA PVT1 modulates the proliferation and apoptosis of lens epithelial cells in diabetic cataract via miR-214-3p/MMP2 axis. J Cell Mol Med. 2020;24(1):554–61. https://doi.org/10.1111/jcmm.14762.CrossRefPubMed

33.

Liu HT, Liu S, Liu L, Ma RR, Gao P. EGR1-mediated transcription of lncRNA-HNF1A-AS1 promotes cell-cycle progression in gastric Cancer. Cancer Res. 2018;78(20):5877–90. https://doi.org/10.1158/0008-5472.CAN-18-1011.CrossRefPubMedPubMedCentral

34.

Ma P, Pan Y, Yang F, Fang Y, Liu W, Zhao C, et al. KLF5-modulated lncRNA NEAT1 contributes to tumorigenesis by acting as a scaffold for BRG1 to silence GADD45A in gastric Cancer. Mol Ther Nucleic Acids. 2020;22:382–95. https://doi.org/10.1016/j.omtn.2020.09.003.CrossRefPubMedPubMedCentral

35.

Jia X, Shi L, Wang X, Luo L, Ling L, Yin J, et al. KLF5 regulated lncRNA RP1 promotes the growth and metastasis of breast cancer via repressing p27kip1 translation. Cell Death Dis. 2019;10(5):373. https://doi.org/10.1038/s41419-019-1566-5.CrossRefPubMedPubMedCentral

36.

Noh JH, Kim KM, McClusky WG, Abdelmohsen K, Gorospe M. Cytoplasmic functions of long noncoding RNAs. Wiley Interdiscip Rev RNA. 2018;9(3):e1471. https://doi.org/10.1002/wrna.1471.CrossRefPubMedPubMedCentral

37.

Zhang J, Cao Z, Yang G, You L, Zhang T, Zhao Y. MicroRNA-27a (miR-27a) in solid tumors: a review based on mechanisms and clinical observations. Front Oncol. 2019;9:893. https://doi.org/10.3389/fonc.2019.00893.CrossRefPubMedPubMedCentral

38.

Li X, Xu M, Ding L, Tang J. MiR-27a: a novel biomarker and potential therapeutic target in tumors. J Cancer. 2019;10(12):2836–48. https://doi.org/10.7150/jca.31361.CrossRefPubMedPubMedCentral

39.

Mizuno K, Mataki H, Arai T, Okato A, Kamikawaji K, Kumamoto T, et al. The microRNA expression signature of small cell lung cancer: tumor suppressors of miR-27a-5p and miR-34b-3p and their targeted oncogenes. J Hum Genet. 2017;62(7):671–8. https://doi.org/10.1038/jhg.2017.27.CrossRefPubMed

40.

Yu N, Yong S, Kim HK, Choi YL, Jung Y, Kim D, et al. Identification of tumor suppressor miRNAs by integrative miRNA and mRNA sequencing of matched tumor-normal samples in lung adenocarcinoma. Mol Oncol. 2019;13(6):1356–68. https://doi.org/10.1002/1878-0261.12478.CrossRefPubMedPubMedCentral

41.

Pitner MK, Taliaferro JM, Dalby KN, Bartholomeusz C. MELK: a potential novel therapeutic target for TNBC and other aggressive malignancies. Expert Opin Ther Targets. 2017;21(9):849–59. https://doi.org/10.1080/14728222.2017.1363183.CrossRefPubMed

42.

Zhang L, Peng R, Sun Y, Wang J, Chong X, Zhang Z. Identification of key genes in non-small cell lung cancer by bioinformatics analysis. Peer J. 2019;7:e8215. https://doi.org/10.7717/peerj.8215.CrossRefPubMedPubMedCentral

43.

Sulzmaier FJ, Jean C, Schlaepfer DD. FAK in cancer: mechanistic findings and clinical applications. Nat Rev Cancer. 2014;14(9):598–610. https://doi.org/10.1038/nrc3792.CrossRefPubMedPubMedCentral

44.

Liu G, Zhan W, Guo W, Hu F, Qin J, Li R, et al. MELK accelerates the progression of colorectal Cancer via activating the FAK/Src pathway. Biochem Genet. 2020;58(5):771–82. https://doi.org/10.1007/s10528-020-09974-x.CrossRefPubMed

45.

Thangaraj K, Ponnusamy L, Natarajan SR, Manoharan R. MELK/MPK38 in cancer: from mechanistic aspects to therapeutic strategies. Drug Discov Today. 2020;25(12):2161–73. https://doi.org/10.1016/j.drudis.2020.09.029.CrossRefPubMed

46.

Janostiak R, Rauniyar N, Lam TT, Ou J, Zhu LJ, Green MR, et al. MELK promotes melanoma growth by stimulating the NF-κB pathway. Cell Rep. 2017;21(10):2829–41. https://doi.org/10.1016/j.celrep.2017.11.033.CrossRefPubMedPubMedCentral

47.

Xu Q, Ge Q, Zhou Y, Yang B, Yang Q, Jiang S, et al. MELK promotes endometrial carcinoma progression via activating mTOR signaling pathway. EBioMedicine. 2020;51:102609. https://doi.org/10.1016/j.ebiom.2019.102609.CrossRefPubMedPubMedCentral

Title: KLF5-induced BBOX1-AS1 contributes to cell malignant phenotypes in non-small cell lung cancer via sponging miR-27a-5p to up-regulate MELK and activate FAK signaling pathway
Authors: Jiang Shi
Chao Yang
Jinlu An
Dexun Hao
Cong Liu
Jumin Liu
Jing Sun
Junguang Jiang
Publication date: 01-12-2021
Publisher: BioMed Central
Keywords: NSCLC
NSCLC
Published in: Journal of Experimental & Clinical Cancer Research / Issue 1/2021
Electronic ISSN: 1756-9966
DOI: https://doi.org/10.1186/s13046-021-01943-5

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 1/2021

The role of patient-derived ovarian cancer organoids in the study of PARP inhibitors sensitivity and resistance: from genomic analysis to functional testing

ITPR3 facilitates tumor growth, metastasis and stemness by inducing the NF-ĸB/CD44 pathway in urinary bladder carcinoma

Correction to: Downregulation of lncRNA ZNF582-AS1 due to DNA hypermethylation promotes clear cell renal cell carcinoma growth and metastasis by regulating the N(6)-methyladenosine modification of MT-RNR1

A cancer-unique glycan: de-N-acetyl polysialic acid (dPSA) linked to cell surface nucleolin depends on re-expression of the fetal polysialyltransferase ST8SIA2 gene

PGRMC1-dependent lipophagy promotes ferroptosis in paclitaxel-tolerant persister cancer cells

Correction to: Linc-SCRG1 accelerates progression of hepatocellular carcinoma as a ceRNA of miR26a to derepress SKP2

Keynote webinar | Spotlight on antibody–drug conjugates in cancer